Bluebird Is Sued Over Patents Related to Blood-Disease Drug

Bluebird Bio’s LentiGlobin and Zynteglo infringe two patents for recombinant vectors used in the treatment of rare blood disorders, closely held Errant Gene Therapeutics claims in a new lawsuit.

• Recombinant vectors deliver gene fragments used in vaccines to boost the immune system
• Bluebird in September submitted to FDA its application for beti-cel, made using BB305 lentiviral vector, and it’s marketing beti-cel as LentiGlobin for treating sickle cell disease and as Zynteglo for beta thalassemia, according to a complaint filed Thursday in federal court in Wilmington, Delaware
• Errant is seeking at least a reasonable royalty and either court order blocking ...